Found: 17
Select item for more details and to access through your institution.
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 3, p. 655, doi. 10.1007/s40120-024-00600-1
- By:
- Publication type:
- Article
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 10, p. 1351, doi. 10.1111/head.14651
- By:
- Publication type:
- Article
Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.
- Published in:
- Journal of Pain Research, 2023, v. 16, p. 1673, doi. 10.2147/jpr.s393854
- By:
- Publication type:
- Article
Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.
- Published in:
- Journal of Pain Research, 2023, v. 16, p. 1311, doi. 10.2147/JPR.S393854
- By:
- Publication type:
- Article
Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01438-4
- By:
- Publication type:
- Article
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
- Published in:
- Cephalalgia, 2022, v. 42, n. 8, p. 769, doi. 10.1177/03331024221076485
- By:
- Publication type:
- Article
Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction.
- Published in:
- European Journal of Neurology, 2022, v. 29, n. 7, p. 2129, doi. 10.1111/ene.15328
- By:
- Publication type:
- Article
Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 4, p. 530, doi. 10.1111/head.14294
- By:
- Publication type:
- Article
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01336-1
- By:
- Publication type:
- Article
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819–828. Epublished November 2020
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, v. 394, n. 11, p. 2343, doi. 10.1007/s00210-021-02156-5
- By:
- Publication type:
- Article
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 9, p. 1376, doi. 10.1111/head.14196
- By:
- Publication type:
- Article
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
- Published in:
- Journal of Headache & Pain, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s10194-021-01279-7
- By:
- Publication type:
- Article
Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
- Published in:
- Human Molecular Genetics, 2016, v. 25, n. 18, p. 3975, doi. 10.1093/hmg/ddw238
- By:
- Publication type:
- Article
A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
- Published in:
- Oncologist, 2016, v. 21, n. 1, p. 7, doi. 10.1634/theoncologist.2015-0152
- By:
- Publication type:
- Article
First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 929, doi. 10.1007/s00280-015-2703-1
- By:
- Publication type:
- Article
Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy.
- Published in:
- Clinical Breast Cancer, 2014, v. 14, n. 2, p. 101, doi. 10.1016/j.clbc.2013.10.001
- By:
- Publication type:
- Article
An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis.
- Published in:
- Nature Biotechnology, 2003, v. 21, n. 3, p. 294, doi. 10.1038/nbt795
- By:
- Publication type:
- Article